Cargando…

Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1–Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda

BACKGROUND: Antiretroviral-based interventions for HIV-1 prevention, including antiretroviral therapy (ART) to reduce the infectiousness of HIV-1 infected persons and pre-exposure prophylaxis (PrEP) to reduce the susceptibility of HIV-1 uninfected persons, showed high efficacy for HIV-1 protection i...

Descripción completa

Detalles Bibliográficos
Autores principales: Baeten, Jared M., Heffron, Renee, Kidoguchi, Lara, Mugo, Nelly R., Katabira, Elly, Bukusi, Elizabeth A., Asiimwe, Stephen, Haberer, Jessica E., Morton, Jennifer, Ngure, Kenneth, Bulya, Nulu, Odoyo, Josephine, Tindimwebwa, Edna, Hendrix, Craig, Marzinke, Mark A., Ware, Norma C., Wyatt, Monique A., Morrison, Susan, Haugen, Harald, Mujugira, Andrew, Donnell, Deborah, Celum, Connie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995047/
https://www.ncbi.nlm.nih.gov/pubmed/27552090
http://dx.doi.org/10.1371/journal.pmed.1002099
_version_ 1782449410889744384
author Baeten, Jared M.
Heffron, Renee
Kidoguchi, Lara
Mugo, Nelly R.
Katabira, Elly
Bukusi, Elizabeth A.
Asiimwe, Stephen
Haberer, Jessica E.
Morton, Jennifer
Ngure, Kenneth
Bulya, Nulu
Odoyo, Josephine
Tindimwebwa, Edna
Hendrix, Craig
Marzinke, Mark A.
Ware, Norma C.
Wyatt, Monique A.
Morrison, Susan
Haugen, Harald
Mujugira, Andrew
Donnell, Deborah
Celum, Connie
author_facet Baeten, Jared M.
Heffron, Renee
Kidoguchi, Lara
Mugo, Nelly R.
Katabira, Elly
Bukusi, Elizabeth A.
Asiimwe, Stephen
Haberer, Jessica E.
Morton, Jennifer
Ngure, Kenneth
Bulya, Nulu
Odoyo, Josephine
Tindimwebwa, Edna
Hendrix, Craig
Marzinke, Mark A.
Ware, Norma C.
Wyatt, Monique A.
Morrison, Susan
Haugen, Harald
Mujugira, Andrew
Donnell, Deborah
Celum, Connie
author_sort Baeten, Jared M.
collection PubMed
description BACKGROUND: Antiretroviral-based interventions for HIV-1 prevention, including antiretroviral therapy (ART) to reduce the infectiousness of HIV-1 infected persons and pre-exposure prophylaxis (PrEP) to reduce the susceptibility of HIV-1 uninfected persons, showed high efficacy for HIV-1 protection in randomized clinical trials. We conducted a prospective implementation study to understand the feasibility and effectiveness of these interventions in delivery settings. METHODS AND FINDINGS: Between November 5, 2012, and January 5, 2015, we enrolled and followed 1,013 heterosexual HIV-1-serodiscordant couples in Kenya and Uganda in a prospective implementation study. ART and PrEP were offered through a pragmatic strategy, with ART promoted for all couples and PrEP offered until 6 mo after ART initiation by the HIV-1 infected partner, permitting time to achieve virologic suppression. One thousand thirteen couples were enrolled, 78% of partnerships initiated ART, and 97% used PrEP, during a median follow-up of 0.9 years. Objective measures of adherence to both prevention strategies demonstrated high use (≥85%). Given the low HIV-1 incidence observed in the study, an additional analysis was added to compare observed incidence to incidence estimated under a simulated counterfactual model constructed using data from a prior prospective study of HIV-1-serodiscordant couples. Counterfactual simulations predicted 39.7 HIV-1 infections would be expected in the population at an incidence of 5.2 per 100 person-years (95% CI 3.7–6.9). However, only two incident HIV-1 infections were observed, at an incidence of 0.2 per 100 person-years (95% CI 0.0–0.9, p < 0.0001 versus predicted). The use of a non-concurrent comparison of HIV-1 incidence is a potential limitation of this approach; however, it would not have been ethical to enroll a contemporaneous population not provided access to ART and PrEP. CONCLUSIONS: Integrated delivery of time-limited PrEP until sustained ART use in African HIV-1-serodiscordant couples was feasible, demonstrated high uptake and adherence, and resulted in near elimination of HIV-1 transmission, with an observed HIV incidence of <0.5% per year compared to an expected incidence of >5% per year.
format Online
Article
Text
id pubmed-4995047
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-49950472016-09-12 Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1–Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda Baeten, Jared M. Heffron, Renee Kidoguchi, Lara Mugo, Nelly R. Katabira, Elly Bukusi, Elizabeth A. Asiimwe, Stephen Haberer, Jessica E. Morton, Jennifer Ngure, Kenneth Bulya, Nulu Odoyo, Josephine Tindimwebwa, Edna Hendrix, Craig Marzinke, Mark A. Ware, Norma C. Wyatt, Monique A. Morrison, Susan Haugen, Harald Mujugira, Andrew Donnell, Deborah Celum, Connie PLoS Med Research Article BACKGROUND: Antiretroviral-based interventions for HIV-1 prevention, including antiretroviral therapy (ART) to reduce the infectiousness of HIV-1 infected persons and pre-exposure prophylaxis (PrEP) to reduce the susceptibility of HIV-1 uninfected persons, showed high efficacy for HIV-1 protection in randomized clinical trials. We conducted a prospective implementation study to understand the feasibility and effectiveness of these interventions in delivery settings. METHODS AND FINDINGS: Between November 5, 2012, and January 5, 2015, we enrolled and followed 1,013 heterosexual HIV-1-serodiscordant couples in Kenya and Uganda in a prospective implementation study. ART and PrEP were offered through a pragmatic strategy, with ART promoted for all couples and PrEP offered until 6 mo after ART initiation by the HIV-1 infected partner, permitting time to achieve virologic suppression. One thousand thirteen couples were enrolled, 78% of partnerships initiated ART, and 97% used PrEP, during a median follow-up of 0.9 years. Objective measures of adherence to both prevention strategies demonstrated high use (≥85%). Given the low HIV-1 incidence observed in the study, an additional analysis was added to compare observed incidence to incidence estimated under a simulated counterfactual model constructed using data from a prior prospective study of HIV-1-serodiscordant couples. Counterfactual simulations predicted 39.7 HIV-1 infections would be expected in the population at an incidence of 5.2 per 100 person-years (95% CI 3.7–6.9). However, only two incident HIV-1 infections were observed, at an incidence of 0.2 per 100 person-years (95% CI 0.0–0.9, p < 0.0001 versus predicted). The use of a non-concurrent comparison of HIV-1 incidence is a potential limitation of this approach; however, it would not have been ethical to enroll a contemporaneous population not provided access to ART and PrEP. CONCLUSIONS: Integrated delivery of time-limited PrEP until sustained ART use in African HIV-1-serodiscordant couples was feasible, demonstrated high uptake and adherence, and resulted in near elimination of HIV-1 transmission, with an observed HIV incidence of <0.5% per year compared to an expected incidence of >5% per year. Public Library of Science 2016-08-23 /pmc/articles/PMC4995047/ /pubmed/27552090 http://dx.doi.org/10.1371/journal.pmed.1002099 Text en © 2016 Baeten et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Baeten, Jared M.
Heffron, Renee
Kidoguchi, Lara
Mugo, Nelly R.
Katabira, Elly
Bukusi, Elizabeth A.
Asiimwe, Stephen
Haberer, Jessica E.
Morton, Jennifer
Ngure, Kenneth
Bulya, Nulu
Odoyo, Josephine
Tindimwebwa, Edna
Hendrix, Craig
Marzinke, Mark A.
Ware, Norma C.
Wyatt, Monique A.
Morrison, Susan
Haugen, Harald
Mujugira, Andrew
Donnell, Deborah
Celum, Connie
Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1–Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda
title Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1–Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda
title_full Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1–Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda
title_fullStr Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1–Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda
title_full_unstemmed Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1–Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda
title_short Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1–Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda
title_sort integrated delivery of antiretroviral treatment and pre-exposure prophylaxis to hiv-1–serodiscordant couples: a prospective implementation study in kenya and uganda
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995047/
https://www.ncbi.nlm.nih.gov/pubmed/27552090
http://dx.doi.org/10.1371/journal.pmed.1002099
work_keys_str_mv AT baetenjaredm integrateddeliveryofantiretroviraltreatmentandpreexposureprophylaxistohiv1serodiscordantcouplesaprospectiveimplementationstudyinkenyaanduganda
AT heffronrenee integrateddeliveryofantiretroviraltreatmentandpreexposureprophylaxistohiv1serodiscordantcouplesaprospectiveimplementationstudyinkenyaanduganda
AT kidoguchilara integrateddeliveryofantiretroviraltreatmentandpreexposureprophylaxistohiv1serodiscordantcouplesaprospectiveimplementationstudyinkenyaanduganda
AT mugonellyr integrateddeliveryofantiretroviraltreatmentandpreexposureprophylaxistohiv1serodiscordantcouplesaprospectiveimplementationstudyinkenyaanduganda
AT katabiraelly integrateddeliveryofantiretroviraltreatmentandpreexposureprophylaxistohiv1serodiscordantcouplesaprospectiveimplementationstudyinkenyaanduganda
AT bukusielizabetha integrateddeliveryofantiretroviraltreatmentandpreexposureprophylaxistohiv1serodiscordantcouplesaprospectiveimplementationstudyinkenyaanduganda
AT asiimwestephen integrateddeliveryofantiretroviraltreatmentandpreexposureprophylaxistohiv1serodiscordantcouplesaprospectiveimplementationstudyinkenyaanduganda
AT habererjessicae integrateddeliveryofantiretroviraltreatmentandpreexposureprophylaxistohiv1serodiscordantcouplesaprospectiveimplementationstudyinkenyaanduganda
AT mortonjennifer integrateddeliveryofantiretroviraltreatmentandpreexposureprophylaxistohiv1serodiscordantcouplesaprospectiveimplementationstudyinkenyaanduganda
AT ngurekenneth integrateddeliveryofantiretroviraltreatmentandpreexposureprophylaxistohiv1serodiscordantcouplesaprospectiveimplementationstudyinkenyaanduganda
AT bulyanulu integrateddeliveryofantiretroviraltreatmentandpreexposureprophylaxistohiv1serodiscordantcouplesaprospectiveimplementationstudyinkenyaanduganda
AT odoyojosephine integrateddeliveryofantiretroviraltreatmentandpreexposureprophylaxistohiv1serodiscordantcouplesaprospectiveimplementationstudyinkenyaanduganda
AT tindimwebwaedna integrateddeliveryofantiretroviraltreatmentandpreexposureprophylaxistohiv1serodiscordantcouplesaprospectiveimplementationstudyinkenyaanduganda
AT hendrixcraig integrateddeliveryofantiretroviraltreatmentandpreexposureprophylaxistohiv1serodiscordantcouplesaprospectiveimplementationstudyinkenyaanduganda
AT marzinkemarka integrateddeliveryofantiretroviraltreatmentandpreexposureprophylaxistohiv1serodiscordantcouplesaprospectiveimplementationstudyinkenyaanduganda
AT warenormac integrateddeliveryofantiretroviraltreatmentandpreexposureprophylaxistohiv1serodiscordantcouplesaprospectiveimplementationstudyinkenyaanduganda
AT wyattmoniquea integrateddeliveryofantiretroviraltreatmentandpreexposureprophylaxistohiv1serodiscordantcouplesaprospectiveimplementationstudyinkenyaanduganda
AT morrisonsusan integrateddeliveryofantiretroviraltreatmentandpreexposureprophylaxistohiv1serodiscordantcouplesaprospectiveimplementationstudyinkenyaanduganda
AT haugenharald integrateddeliveryofantiretroviraltreatmentandpreexposureprophylaxistohiv1serodiscordantcouplesaprospectiveimplementationstudyinkenyaanduganda
AT mujugiraandrew integrateddeliveryofantiretroviraltreatmentandpreexposureprophylaxistohiv1serodiscordantcouplesaprospectiveimplementationstudyinkenyaanduganda
AT donnelldeborah integrateddeliveryofantiretroviraltreatmentandpreexposureprophylaxistohiv1serodiscordantcouplesaprospectiveimplementationstudyinkenyaanduganda
AT celumconnie integrateddeliveryofantiretroviraltreatmentandpreexposureprophylaxistohiv1serodiscordantcouplesaprospectiveimplementationstudyinkenyaanduganda
AT integrateddeliveryofantiretroviraltreatmentandpreexposureprophylaxistohiv1serodiscordantcouplesaprospectiveimplementationstudyinkenyaanduganda